Back to top

crispr: Archive

Zacks Equity Research

Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss

Allogene's (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.

GSKPositive Net Change ANIPPositive Net Change ADMAPositive Net Change ALLONegative Net Change

Zacks Equity Research

Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology

Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.

GSKPositive Net Change ANIPPositive Net Change ADMAPositive Net Change ALLONegative Net Change

Zacks Equity Research

Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up

Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.

VRTXPositive Net Change ACETNegative Net Change EDITNegative Net Change AKRONegative Net Change

Zacks Equity Research

CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up

CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.

VRTXPositive Net Change PBYIPositive Net Change ADMAPositive Net Change CRSPNegative Net Change